Microsaic Systems announces bioprocessing partnership

Microsaic Systems on Monday partnered with the Centre for Process Innovation (CPI) to use its UK biotherapeutics facility to investigate the potential use of mass spectrometry (MS) instruments in bioprocessing.

From January, the AIM traded company will begin a 12 month programme that is intended to deliver an on-line, and real-time method for bioreactor chemical analysis and control.

Microsaic said its point-of-need MS detector will be integrated with "closed-loop" software to control the overall system and provide data analytics and continuous, real-time control of the biomanufacturing process.

The company added that, as the biomanufacturing industry has become subject to increasing demands from regulatory agencies, it was confident that its MS-based solution could help businesses satisfy new requirements.

Chief executive Glenn Tracey said: "We are very pleased to be working with the CPI on this project, which brings together our combined expertise in analytical instrumentation and biologics manufacturing. Importantly, we are not aware of any other technology which can measure simultaneously small and large molecules in-situ, enabling real-time bioreactor control within a closed loop system."

Tracey added that market and customer feedback had reassured him that the company's offering was ahead of all others in the field.

Microsaic Systems shares were up by 5.14% at 1.12p at 1435 GMT.